Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8528190 | Clinical Therapeutics | 2018 | 20 Pages |
Abstract
Fixed-dose combinations of ezetimibe/rosuvastatin significantly improved lipid profiles in patients with hypercholesterolemia compared with rosuvastatin monotherapy. All groups treated with rosuvastatin and ezetimibe reported a decrease in mean LDL-C level >50%. The safety and tolerability of ezetimibe/rosuvastatin therapy were comparable with those of rosuvastatin monotherapy. ClinicalTrials.gov identifier: NCT02749994.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Soon Jun MD, PhD, Han Saem MD, Jeong Cheon MD, PhD, Dong-Hun MD, PhD, Kyung Heon MD, PhD, Weon MD, PhD, Sang Kyoon MD, PhD, Seok-Yeon MD, PhD, Byung-Su MD, PhD, Ki Chul MD, PhD, Seung-Woon MD, PhD, Joon-Han MD, PhD, Kyoo Rok MD, PhD, Wook Sung MD, PhD,